BNP Paribas Financial Markets
DWTX

BNP Paribas Financial Markets’s Dogwood Therapeutics DWTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4 Hold
2
– – ﹤0.01% 5785
2025
Q4 		$8 Sell
2
-8
-80% -$47 ﹤0.01% 5698
2025
Q3 		$77 Buy
+10
New +$50 ﹤0.01% 5451

Other funds holding DWTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

BNP Paribas Financial Markets's DWTX Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Dogwood Therapeutics (DWTX) position steady in Q1 2026 at 2 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #5785.

BNP Paribas Financial Markets first reported a position in DWTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $77 in Q3 2025. 13 funds tracked by Wall St. Rank hold DWTX as of Q1 2026.

  • BNP Paribas Financial Markets held 2 shares of Dogwood Therapeutics worth $4 as of Q1 2026.
  • BNP Paribas Financial Markets left its Dogwood Therapeutics share count unchanged in Q1 2026.
  • Dogwood Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5785 holding.
  • BNP Paribas Financial Markets first reported a position in Dogwood Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • BNP Paribas Financial Markets's Dogwood Therapeutics position peaked at $77 in Q3 2025.
  • 13 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.